The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|November 5, 2018
Immunotherapy Potential in Locally Advanced CSCC
Immunotherapy Potential in Locally Advanced CSCC
Advertisement
A 69-Year-Old Man With Advanced CSCC
- History and physical exam
- An otherwise healthy, 69-year-old male, fair skinned, retired construction worker, widow
- Presented to his PCP with what he described as a wound that was not healing behind his ear; he reported first noticing it at least 6 months ago and complained of recent onset of numbness in the area.
- ECOG PS 1
- The visible, ulcerated lesion was 4.5-cm in diameter and >5-mm deep
- No palpable nodes
- Biopsy confirmed a poorly-differentiated, infiltrative, postauricular cutaneous squamous cell carcinoma lesion with 7-mm invasion into subcutaneous fat.
- The recommended definitive surgical approach involved partial auriculectomy; the patient declined.
- Cemiplimab 3 mg/kg q2w was initiated
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5